Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P08908 (5-HT1A)
 5,574 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

5-Hydroxytryptamine (5-HT) receptors have been analyzed and related to potential roles played by 5-HT in the physiology of the enteric nervous system (ENS). Three subtypes of 5-HT receptor--5-HT1P, 5-HT3, and 5-HT1A--have been found on enteric neurons. Receptors have been identified by intracellularly recording the electrical activity of enteric neurons and by studying the binding of radioligands and polyclonal anti-idiotypic antibodies raised against antibodies to 5-HT. Radioligand binding has been assessed by rapid filtration and by radioautography. 5-HT1P receptors mediate slow depolarizations of myenteric neurons that are associated with a closure of K+ channels. These responses can be inhibited by N-acetyl-hydroxytryptophyl-5-hydroxytryptophan amide (5-HTP-DP) and by the substituted benzamide, BRL 24924. 5-HT1P-like responses can be mimicked by 5- and 6-hydroxyindalpine, by another substituted benzamide, the S stereoisomer of zacopride, and by anti-idiotypic antibodies. 5-HT1P receptors can be labeled by 3H-5-HT and 3H-5-hydroxyindalpine with high affinity and are located on neurons of both enteric plexuses and on processes of intrinsic neurons in the gastrointestinal mucosa. A similar distribution of binding sites for anti-idiotypic antibodies is revealed by immunocytochemistry. Excitatory postsynaptic potentials (EPSPs) mediated by 5-HT are abolished by 5-HT1P antagonists. Blockade of 5-HT1P receptors is accompanied by acceleration of the rate of gastric emptying. Mucosal application of cholera toxin activates enteric neurons in both plexuses; this action is blocked by 5-HT1P or 5-HT3 antagonists and by anti-idiotypic antibodies. 5-HT3 receptors are responsible for fast depolarizations associated with increased membrane conductance. These responses are antagonized by ICS 205-930 and mimicked by 2-methyl-5-HT and anti-idiotypic antibodies. 5-HT1A receptors have been reported to mediate hyperpolarizing responses associated with a rise in membrane conductance. Hyperpolarizing responses are also elicited by the 5-HT1A agonists, 8-hydroxy-di-n-propylaminotetralin (8-OH-DPAT) and 5-carboxyamidotryptamine. It is proposed that 5-HT1P receptors and perhaps 5-HT3 receptors are involved in initiating the peristaltic reflex and in regulating gastric emptying. No physiologic role has yet been identified for 5-HT1A receptors in the ENS.
 ...
PMID:5-HT receptor subtypes outside the central nervous system. Roles in the physiology of the gut. 207 74

The present study was conducted to investigate the effects of various 5-hydroxytryptamine (5-HT) agonists and antagonists on motor behaviour in rats and marmosets. Various motor-based responses were assessed after central or peripheral administration of 5-HT agents to rats and marmosets. Drugs acting as agonists at the 5-HT1A receptor (8-OHDPAT, gepirone, BMY-7378, NAN-190, PAPP (LY165163) and flesinoxan) and 5-HT2/1C receptors (DOI) were found to reverse neuroleptic-induced catalepsy in the rat whereas 5-HT2/1C antagonists (mianserin, ritanserin and ICI-170,809) and the 5-HT1 antagonist ((+/-)pindolol) increased catalepsy. Agonists acting at 5-HT3 receptors (phenylbiguanide and 2-methyl-5-HT) had no effect on catalepsy. The putative 5-HT1A antagonist, (+/-) pindolol, attenuated the reversal of catalepsy by 8-OHDPAT. Although both 8-OHDPAT and BMY-7378 were tested, only the latter was found to reduce apomorphine-induced stereotypy. Bilateral or unilateral infusions of 8-OHDPAT, BMY-7378 or pindolol into the substantia nigra of non-lesioned rats had no effect on spontaneous locomotor or rotational activity, respectively. However, 8-OHDPAT and BMY-7378 were found to increase or decrease motor activity, after injection into the median or dorsal raphe nuclei, respectively. Finally, 8-OHDPAT and BMY-7378 were found to be inactive against MPTP-induced bradykinesia in the marmoset. It is concluded that both 5-HT1A and 5-HT2/1C receptors are involved in the anti-cataleptic effects of 5-HT agents. The 5-HT1A receptors are probably situated within the raphe, whereas the location of the 5-HT2/1C receptors remains undetermined.
 ...
PMID:Behavioural effects of serotonin agonists and antagonists in the rat and marmoset. 212 71

5-Hydroxytryptamine (5-HT) receptors were originally subclassified into the subtypes M and D based on the findings that 5-HT contracted the guinea-pig ileum by two different mechanisms: (a) directly by an effect on receptors located on smooth muscles (via D receptors), and (b) indirectly by an effect on neuronal receptors (M receptors), the activation of which caused acetylcholine release. With the introduction of radioligand-binding studies and the development of more selective 5-HT agonists and antagonists, it rapidly became apparent that this subclassification is an oversimplification, and it is now accepted that at least three, possibly four main families of 5-HT receptors exist: 5-HT1, 5-HT2, 5-HT3 and possibly 5-HT4 receptors. Furthermore, 5-HT1 receptors are not a homogeneous class, but are subdivided further into four subtypes: 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D. Whether 5-HT2 and 5-HT3 receptors are also a heterogeneous class of receptors is still a matter of controversy. Besides the differences in specific agonists and antagonists, 5-HT-receptor subtypes seem to differ also in their signal-transduction mechanisms. 5-HT1 receptors (with the exception of 5-HT1C) are coupled to adenylate cyclase, predominantly in an inhibitory fashion, but 5-HT1-mediated activation of adenylate cyclase has been also described. 5-HT2 receptors (and 5-HT1C) are coupled to PI turnover, while 5-HT3 receptors appear to be coupled directly to fast ion channels. On the other hand, 5-HT4 receptors couple obviously in an excitatory fashion to adenylate cyclase.
 ...
PMID:5-Hydroxytryptamine-receptor subtypes. 213 74

Serotonin (5-HT) induced a transient decrease followed by an increase and then a longer-lasting decrease in blood pressure. The initial decrease in blood pressure results from a reduction in cardiac output as a result of the profound bradycardia. The secondary increase in blood pressure is caused by an increase in both cardiac output and total peripheral resistance. The final decrease in blood pressure is ascribed to a reduction in total peripheral resistance. The effects of 5-HT on regional haemodynamics are known to vary according to the vascular bed and even in the same vascular bed. Accordingly, 5-HT induced either vasoconstriction or vasodilatation. Vasoconstriction occurred in most cases in large arteries and is due to stimulation of 5-HT2 receptors. However, 5-HT1-like receptors are probably also implicated. 5-HT-induced vasodilatation is attributed to stimulation of 5-HT1-like receptors. However, limited evidence suggests also an implication of 5-HT3 and even 5-HT2 receptors in the dilator effects of 5-HT. 5-HT1A receptor agonists decreased blood pressure by a reduction in total peripheral resistance. This vasodilatation seems to be widespread. Other 5-HT1-like receptor agonists have differential effects according to the animal species used.
 ...
PMID:Haemodynamic aspects and serotonin. 213 76

The behavioural specificity of the hyperphagic effects of 8-OH-DPAT is a controversial issue. The present study addressed this question through the introduction of behavioural competition. Feeding behaviour in male mice was assessed under both basal (free-feeding) and social conflict conditions. Since, in the latter condition, defence and escape are prepotent responses, elicitation of feeding would be indicative of a specific treatment effect on mechanisms controlling food intake. Results showed that 8-OH-DPAT enhanced basal feeding duration (at doses of 0.05-0.50 mg/kg) and also elicited feeding in intruder mice during encounters with aggressive resident conspecifics (at doses of 0.10-0.50 mg/kg). As the 5-HT3 antagonist GR38032F (1.0-2.0 mg/kg) enhanced feeding only under basal conditions, the effect of 8-OH-DPAT cannot readily be attributed to anxiety reduction. Finally, diazepam (1.0-2.0 mg/kg) produced a similar profile to that of 8-OH-DPAT, suggesting that the hyperphagic effects of the 5-HT1A agonist are not pharmacologically specific.
 ...
PMID:8-OH-DPAT specifically enhances feeding behaviour in mice: evidence from behavioural competition. 214 47

The effects of serotonergic activation on cold-stimulated thyrotropin (TSH) and prolactin secretion were studied in male rats. Peripheral injections of both 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), a 5-HT1A receptor agonist, and 1-(3-chlorophenyl)piperazine (m-CPP), a 5-HT1 agonist, decreased TSH levels. The action of 8-OH-DPAT was antagonized by (+/-)-pindolol, which is known to have 5-HT1 antagonist activity, but not by metergoline or ketanserin. The action of m-CPP was antagonized by ketanserin but not by metergoline. TSH levels were not affected by a 5-HT3 receptor agonist, 2-methyl-5-HT, or by a 5-HT3 antagonist, MDL 72222. Infusion of 8-OH-DPAT into the anterior third ventricle increased TSH levels; 5-HT tended to increase TSH levels, but the effect was not significant. Inversely, infusion of 5-HT, 8-OH-DPAT or m-CPP into the posterior third ventricle decreased TSH levels. The action of 5-HT was counteracted by metergoline, ketanserin and (+/-)-pindolol. Unexpectedly, m-CPP infusion into the anterior third ventricle also inhibited TSH secretion. The prolactin-elevating effects of 5-HT, 8-OH-DPAT and m-CPP were neither consistent nor site-specific. In conclusion, stimulation of both 5-HT1 and 5-HT2 receptors may inhibit TSH secretion, but the exact mechanism underlying the site-dependent action of 5-HT and 8-OH-DPAT on TSH secretion remains to be identified.
 ...
PMID:Complex actions of serotonergic agonists on cold-stimulated TSH secretion in male rats. 214 94

The cardiovascular response to flesinoxan and 8-OH-DPAT (8-hydroxy-2-(di-N-propylamino)tetralin), 5-HT1A receptor agonists, has been investigated in anaesthetized Wistar rats and spontaneously hypertensive rats (SHR) and in conscious SHR. Flesinoxan and 8-OH-DPAT potently lowered blood pressure and heart rate in these models. In conscious SHR, atropine reversed the bradycardia induced by flesinoxan partially and that induced by 8-OH-DPAT completely. In pithed rats with vasopressin-raised blood pressure, neither flesinoxan nor 8-OH-DPAT lowered blood pressure or heart rate. Intracisternal administration of either flesinoxan or 8-OH-DPAT was less efficacious than intravenous administration. The cardiovascular responses to flesinoxan and 8-OH-DPAT in the anaesthetized Wistar were inhibited by the putative 5-HT1A antagonists methiothepin, buspirone, spiroxatrine and 8-MeO-C1EPAT (8-methoxy-2-(N-2-cholroethyl-N-n-propylamino)tetralin). 8-MeO-C1EPAT appeared to be the most suitable antagonist in this model. The 5-HT1C, antagonist ritanserin or the 5-HT3 antagonist GR 38032F had no effect on the responses to flesinoxan or 8-OH-DPAT. In conscious SHR however, 8-MeO-C1EPAT did not antagonize these cardiovascular responses. This study confirms the involvement of central 5-HT1A receptors in the cardiovascular effects of flesinoxan and 8-OH-DPAT.
 ...
PMID:Comparison of the cardiovascular effects of the 5-HT1A receptor agonist flesinoxan with that of 8-OH-DPAT in the rat. 214 96

The past decade has seen important advances in the clinical use of serotonergic agents. The authors summarize the current status of selective agents for 5-HT receptor subtypes and their utility in the treatment of human neuropsychiatric disorders. The putative novel anxiolytic effects of 5-HT1A partial agonists such as buspirone, the unique and potent antiemetic effects of 5-HT3 antagonists in cancer chemotherapy, and the antidepressant effects of selective 5-HT uptake blockers such as fluoxetine are excellent examples of the clinical relevance of selective 5-HT receptor agents. The increasing ability to modulate serotonergic neurotransmission via distinct serotonin (5-HT) receptor subtypes should greatly facilitate the analysis of the role of 5-HT in both normal and abnormal human brain function.
 ...
PMID:Serotonin receptor and reuptake sites: pharmacologic significance. 215 1

Work on the pharmacological effects of high-dose metoclopramide led Beecham scientists to identify the role of 5-HT3 receptors in the emetic response to cytostatic drugs and X-irradiation in animals. Further studies have confirmed and extended knowledge of the novel 5-HT3 antagonist granisetron. Dose-dependent inhibition of the 5-HT-induced Bezold-Jarisch reflex in anaesthetized rats was shown by doses of 0.1-10 micrograms/kg i.v. granisetron. Radioligand binding studies in rat brain revealed a high affinity (Ki 0.26 nM) for 5-HT3 sites and much lower affinities (Ki 1000 - greater than 10,000 nM) for 5-HT1, 5-HT2, 5-HT1A, 5-HT1B/C, 5-HT1C, alpha 1, alpha 2, dopamine D2, benzodiazepine, picrotoxin, beta, histamine H1 or opioid mu, kappa or delta binding sites. Granisetron was effective prophylactically after oral or i.v. doses or by intervention after i.v. doses (0.005-0.5 mg/kg) against cisplatin, cyclophosphamide and doxorubicin or X-irradiation-induced emesis in the conscious ferret in the absence of any side effects. It was concluded therefore, that granisetron is a selective and potent anti-emetic worthy of clinical investigation.
 ...
PMID:The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis. 216 86

Over the past decade, a variety of serotonin (5-hydroxytryptamine, 5-HT) receptor/binding sites have been identified. These include 5-HT1, 5-HT2, and 5-HT3 sites. The 5-HT1 sites have been further divided into 5-HT1A, 5-HT1B, 5-HT1C, 5-HT1D and 5-HT1E sites. It would be of interest to identify those pharmacological effects that are specifically mediated by a particular population of 5-HT sites and, indeed, attempts have been made to do this almost since the initial discovery of multiple populations of sites. Unfortunately, much of the early work made use of serotonergic agents that are now known to be somewhat less selective than originally suspected. Nevertheless, there is ample information in the literature suggesting that site-selective serotonergic agents may ultimately lead (and, in some cases, has already led) to the development of therapeutically-useful agents. The present review examines the pharmacological effects that are thought to be related to the individual types of 5-HT sites and provides some clinical implications for agents that act at these sites.
 ...
PMID:Serotonin receptors: clinical implications. 218 98


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>